The Potential Synergistic Risk of Albuterol and Vasoactives in Acute Lung Injury Trials.

Sultan AlmuntashiriAaron ChaseAndrea Sikora Newsome Duo Zhang

Published in: The Annals of pharmacotherapy (2022)

This study has shown fewer VFDs for patients who received both vasoactive and albuterol. There were also fewer ICU-free days when compared to those on vasoactive only. Given the common use of both agents, a prospective evaluation of the additive adverse effects of beta-agonism is warranted.

Keyphrases

intensive care unit
lipopolysaccharide induced
lps induced
cancer therapy
risk assessment
drug delivery
human health
climate change